The objective of the current research is to evaluate the biological functions of METase-pemetrexed-loaded PEG–PLGA NPs modified with anti-CD133–scFV on SGC 7901 in the treatment of gastric carcinoma. This evidence concerns the gene PROM1 and gastric carcinoma.